Ordena

Cercar

01/05/2022 Digital PET vs Analog PET: Clinical Implications?
López-Mora D.A., Carrió I., Flotats A.. Digital PET vs Analog PET: Clinical Implications?. SEMINARS IN NUCLEAR MEDICINE. 2022; 52(3)DOI:10.1053/j.semnuclmed.2021.10.004. PMID:34836617. IF:4.900(Q1/2D).
01/05/2022 The Effect of Enteral Immunonutrition in the Intensive Care Unit: Does It Impact on Outcomes?
Lopez-Delgado, JC, Grau-Carmona, T, Trujillano-Cabello, J, Garcia-Fuentes, C, Mor-Marco, E, Bordeje-Laguna, ML, Portugal-Rodriguez, E, Lorencio-Cardenas, C, Vera-Artazcoz, P, Macaya-Redin, L, Martinez-Carmona, JF, Mateu-Campos, L, Gero-Escapa, M, Gastaldo-Simeon, R, Vila-Garcia, B, Flordelis-Lasierra, JL, Montejo-Gonzalez, JC, Servia-Goixart, L. The Effect of Enteral Immunonutrition in the Intensive Care Unit: Does It Impact on Outcomes?. Nutrients. 2022; 14(9)DOI:10.3390/nu14091904. PMID:35565870. IF:5.900(Q1/2D).
01/05/2022 Cost-utility analysis of venetoclax in combination with obinutuzumab as first-line treatment of chronic lymphocytic leukaemia in Spain
Moreno-Martinez, E, de la Serna-Torroba, J, Escudero-Vilaplana, V, Hernandez-Rivas, JA, Sanchez-Cuervos, M, Sanchez-Hernandez, R. Cost-utility analysis of venetoclax in combination with obinutuzumab as first-line treatment of chronic lymphocytic leukaemia in Spain. Farmacia Hospitalaria. 2022; 46(3)DOI:10.7399/fh.11829. PMID:36183205. IF:(Q/D).
01/05/2022 Autochthonous and imported tegumentary leishmaniasis in Catalonia (Spain): Aetiological evolution in the last four decades and usefulness of different typing approaches based on biochemical, molecular and proteomic markers
Fernandez-Arevalo, A, Ballart, C, Munoz-Basagoiti, J, Basarte, L, Lobato, G, Arnau, A, Abras, A, Tebar, S, Llovet, T, Lami, P, Pratlong, F, Alsina, M, Roe, E, Puig, L, Munoz, C, Gallego, M. Autochthonous and imported tegumentary leishmaniasis in Catalonia (Spain): Aetiological evolution in the last four decades and usefulness of different typing approaches based on biochemical, molecular and proteomic markers. Transboundary and Emerging Diseases. 2022; 69(3)DOI:10.1111/tbed.14107. PMID:33864706. IF:4.300(Q1/1D).